English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

CDIBP Buys Vaccine Conjugate Technology from FinaBio

Aug. 18, 2012

FinaBio, a research and development stage biotechnology company focused on developing affordable conjugate vaccines, and the Chengdu Institute of Biological Products Co., Ltd (CDIBP) announced their agreement to license Finabio’s conjugate vaccine technology for the development and manufacturing of Pneumococcal conjugate vaccines in China. The agreement will accelerate the multi-valent Pneumococcal vaccine development program at CDIBP.
The structure of the license in China includes an upfront payment, payments based on achievement of Chinese regulatory milestones, and royalty payments that are contingent upon successful development and commercialization.